97% of our viewers don't realise they aren't followed, please double check, thank you!
What does it really take to back and build world-class biotech companies from idea to FDA approval?
This week on Leading Beyond the Lab, Lawrence Rose sat down with Jonathan Tobin, Partner at Brandon Capital, to explore what truly drives success in life-science venture capital.
With over 20 years' experience spanning biotech investment, company creation, board leadership, and early-stage venture building, Jonathan has played a key role in building and scaling biotech companies across Europe, Australia and the US.
In this episode Jonathan covers:
- How Brandon Capital was co-founded in Australia by Chris Nave and Stephen Thompson, who grew it into a globally respected life sciences VC firm spanning company creation, long-term funding, and expansion in the US and UK.
- Jonathan reflects on how Brandon Capital has helped shape the Australian biotech ecosystem over the last almost 2 decades.
- Investments like AstronauTx, AdvanCell, Myricx Bio, and the stories from the frontline, including strategic pivots, tough decisions, successful exits, and the high-conviction bets that shaped portfolio outcomes.
- Practical, investor-led advice for founders raising venture capital; covering readiness, storytelling, common mistakes, and how to stand out in competitive funding rounds.
- How CatalYm has progressed deep into the clinic, and why Brandon Capital has supported the company through multiple funding rounds.
- Jonathan’s outlook on the future of biotech, from neuroscience and radiopharmaceuticals, to overlooked white-space opportunities shaping the next innovation cycle.
Be sure to check out the full episode of Leading Beyond the Lab, and don’t forget to like, subscribe, and share with anyone building in biotech.
To listen to (or watch) the full episode, search \"Leading Beyond The Lab Jonathan Tobin\" on your preferred streaming platform.
","author_name":"ARTO Talent"}